Back to top
more

Celldex Therapeutics (CLDX)

(Delayed Data from NSDQ)

$21.80 USD

21.80
790,306

-0.39 (-1.76%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $21.79 -0.01 (-0.05%) 5:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Celldex Begins Phase I Trial on Cancer Candidate CDX-1140

by Zacks Equity Research

Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.

    Zacks Equity Research

    Celldex (CLDX) Initiates Phase II Study on Cancer Candidate

    by Zacks Equity Research

    Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.

      Zacks Equity Research

      Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up

      by Zacks Equity Research

      Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

        Zacks Equity Research

        Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?

        by Zacks Equity Research

        With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

          Zacks Equity Research

          Celldex Ends Phase II Enrollment for Breast Cancer Candidate

          by Zacks Equity Research

          Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.

            Zacks Equity Research

            Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up

            by Zacks Equity Research

            Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

              Zacks Equity Research

              What's in the Cards for Celldex (CLDX) this Earnings Season?

              by Zacks Equity Research

              With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                Zacks Equity Research

                Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report?

                by Zacks Equity Research

                Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Zacks Equity Research

                  Celldex's Immuno-Oncology Pipeline Continues to Impress

                  by Zacks Equity Research

                  On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

                    Zacks Equity Research

                    Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up

                    by Zacks Equity Research

                    Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate

                      Zacks Equity Research

                      Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?

                      by Zacks Equity Research

                      Celldex Therapeutics, Inc. (CLDX) is expected to report first-quarter 2017 results on May 4. Celldex's performance has been encouraging with a three-quarter average positive surprise of 8.06%.

                        Zacks Equity Research

                        What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?

                        by Zacks Equity Research

                        GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.

                          Zacks Equity Research

                          Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?

                          by Zacks Equity Research

                          We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.

                            Zacks Equity Research

                            Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

                            by Zacks Equity Research

                            Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.

                              Zacks Equity Research

                              What's in Store for Biogen (BIIB) this Earnings Season?

                              by Zacks Equity Research

                              Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.

                                Zacks Equity Research

                                Why Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report?

                                by Zacks Equity Research

                                Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Zacks Equity Research

                                  Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

                                  by Zacks Equity Research

                                  Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

                                    Zacks Equity Research

                                    Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat

                                    by Zacks Equity Research

                                    Spectrum Pharmaceuticals, Inc. (SPPI) reported a loss of 22 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 26 cents but substantially wider than year-ago loss of 6 cents.

                                      Zacks Equity Research

                                      Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

                                      by Zacks Equity Research

                                      Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.